Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: Charles Holewinski who wrote (564)	3/16/1998 1:12:00 AM
From: flickerful	Read Replies (1) \| Respond to of 756

good question, charles... i have learned, however, jackson has distinctly logical reasons for his trading decisions; however, i would be interested to hear this particular rationale myself.

To: Charles Holewinski who wrote (564)	3/16/1998 6:15:00 AM
From: 5,17,37,5,101,...	Respond to of 756

Well, if you recall last September when the FDA panel accepted Paxene for further FDA consideration, IVX stock price rocketed from $8.94 to $12.50 on 1,000,000+ volume. Unfortunately IVX didn't bother to let shareholders know that BM-S had secured orphan status for Paclitaxel for use against K-S and the stock price dropped to $6.18. Your question about calls implies the probability of an IVX merger. While a merger is the logical option for Frost, he probably won't sell for less than $16.00. A merger is the only reason for holding this rare specimen of canine past $10.00. (see previous post for Oppenheimer report valuing of IVX at $7.50 as retail investment). I have to say I don't look at option pricing, so I'm unable to interpret. My own gut feeling tells me Frost will have a difficult time finding a buyer at $14.00. If you believe the generic drug industry has glowing prospects, you are likely correct, but IVX is IMHO not the correct investment vehicle. Watson or Mylan have a better record of creating shareholder value with sound business decisions. Over the years management has shown no interest in reducing crazy exorbitant G&A expenses. They hold onto useless assets. They have hoodwinked shareholders with various schemes from hollow sales scams to disingenuous mergers. They have shown a cavalier disregard for shareholder interest. I will sell into a price spike that comes on the heels of better than expected earnings or a drug approval, especially if they issue a sugar coated press release. Jackson